Elevated CSF levels of sTREM2 are associated with slower tau aggregation in Aβ-positive individuals who do not yet exhibit dementia, suggesting that sTREM2 may delay tau-related neurodegeneration in the preclinical stages of AD [133]. This evidence concerns the gene MAPT and Alzheimer disease.